Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Shamyla Siddique"'
Autor:
Kristian Brock, Lucinda Billingham, Mhairi Copland, Shamyla Siddique, Mirjana Sirovica, Christina Yap
Publikováno v:
BMC Medical Research Methodology, Vol 17, Iss 1, Pp 1-15 (2017)
Abstract Background The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase.
Externí odkaz:
https://doaj.org/article/a6d8997746254f59bbccffbcfb03e26d
Autor:
Khaled M. Musallam, Wesam Ahmed, Mozah Obaid Almarshoodi, Omar Trad, Naser Al Zein, Shamyla Siddique, Nastaran Shekary, Sulaima Daboul, Shahrukh Hashmi
Publikováno v:
Annals of Hematology.
Posttransplant MRD and T-cell chimerism status predict outcomes in patients allografted with AML/MDS
Autor:
Justin Loke, Nicholas McCarthy, Aimee E Jackson, Shamyla Siddique, Andrea Hodgkinson, John Mason, Charles R Crawley, Maria Gilleece, Andrew J Peniket, Rachel Protheroe, Rahuman Salim, Eleni Tholouli, Keith WIlson, Georgia Andrew, Richard Dillon, Naeem Khan, Victoria Potter, Pramila Krishnamurthy, Charles Craddock, Sylvie D Freeman
Publikováno v:
Blood Advances.
Allogeneic stem-cell transplantation allows the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR ex
Autor:
Paresh Vyas, Jamie D. Cavenagh, Michael Dennis, Shamyla Siddique, Richard J. Kelly, Srinivas P. Pillai, Mary Frances McMullin, Keith Wheatley, Louise Dudley, Sandeep Nagra, Manoj Raghavan, Angela Hamblin, Alison Kennedy, Natalia Garcia-Martin, Marlen Metzner, Corran Roberts, Emma Gbandi, Paul Ferguson, Lynn Swun Quek, Aimee E. Houlton, Charles F. Craddock
Table S3. Variants detected by NGS targeted re-sequencing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30cac8136a16ee1bad22e1c2d07a962d
https://doi.org/10.1158/1078-0432.22468974.v1
https://doi.org/10.1158/1078-0432.22468974.v1
Autor:
Paresh Vyas, Jamie D. Cavenagh, Michael Dennis, Shamyla Siddique, Richard J. Kelly, Srinivas P. Pillai, Mary Frances McMullin, Keith Wheatley, Louise Dudley, Sandeep Nagra, Manoj Raghavan, Angela Hamblin, Alison Kennedy, Natalia Garcia-Martin, Marlen Metzner, Corran Roberts, Emma Gbandi, Paul Ferguson, Lynn Swun Quek, Aimee E. Houlton, Charles F. Craddock
Table S1. Details for NGS amplicons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2349da5f2731fe9b5293126d52cd1ddb
https://doi.org/10.1158/1078-0432.22468977.v1
https://doi.org/10.1158/1078-0432.22468977.v1
Autor:
Paresh Vyas, Jamie D. Cavenagh, Michael Dennis, Shamyla Siddique, Richard J. Kelly, Srinivas P. Pillai, Mary Frances McMullin, Keith Wheatley, Louise Dudley, Sandeep Nagra, Manoj Raghavan, Angela Hamblin, Alison Kennedy, Natalia Garcia-Martin, Marlen Metzner, Corran Roberts, Emma Gbandi, Paul Ferguson, Lynn Swun Quek, Aimee E. Houlton, Charles F. Craddock
Table S2. Details of Exons covered Table S4. Details of antibodies/ streptavidin used Table S5. Summary of longitudinal progenitor LSC quantitation by FACS Table S6. Overview of toxicities Figure S1. Progenitor LSC FACS gating strategy Figure S2. Kap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4008f6bb20cdb6eb9a1403c23f11f16
https://doi.org/10.1158/1078-0432.22468971.v1
https://doi.org/10.1158/1078-0432.22468971.v1
Autor:
Paresh Vyas, Jamie D. Cavenagh, Michael Dennis, Shamyla Siddique, Richard J. Kelly, Srinivas P. Pillai, Mary Frances McMullin, Keith Wheatley, Louise Dudley, Sandeep Nagra, Manoj Raghavan, Angela Hamblin, Alison Kennedy, Natalia Garcia-Martin, Marlen Metzner, Corran Roberts, Emma Gbandi, Paul Ferguson, Lynn Swun Quek, Aimee E. Houlton, Charles F. Craddock
Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML), but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0327fb5df6da2c1e7558e937576087
https://doi.org/10.1158/1078-0432.c.6527109
https://doi.org/10.1158/1078-0432.c.6527109
Autor:
Ikhlaaq Ahmed, Andrea Hodgkinson, Rebecca Bishop, Ram Malladi, Jane Nunnick, Shamyla Siddique, Aimee Jackson, Fiona L Dignan, Mohamed Elhaneid, Graham McIlroy, Paul Moss, Charles Craddock, Rachel Protheroe
Publikováno v:
Bone Marrow Transplantation. 56:2948-2955
Chronic graft-versus-host disease (cGvHD) is a major cause of non-relapse morbidity and mortality following allogeneic stem cell transplant. Over half of patients with moderate or severe cGvHD fail to respond adequately to first-line treatment with s
Autor:
Aimee Jackson, Sylvie D. Freeman, Ann Hunter, Richard Dillon, Victoria T Potter, Georgia Andrew, Jiri Pavlu, Rahuman Salim, Sandeep Nagra, Ram Malladi, Shamyla Siddique, Eleni Tholouli, Rachel Protheroe, Naeem Khan, Keith Wheatley, Keith G. Wilson, Nicholas I. McCarthy, Charles Craddock, Jenny Byrne, Anne Parker, Maria H. Gilleece, Andrea Hodgkinson, Justin Loke, Andrew Peniket, John Mason, Paresh Vyas, Charles Crawley
Publikováno v:
Journal of Clinical Oncology. 39:768-778
PURPOSE Reduced-intensity conditioning (RIC) regimens have extended the curative potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid leukemia (AML) and myelodysplasia (MDS) but are associated with a high ris
Autor:
Daniel Slade, Rachel Wheat, Wendy Ingram, Michael Dennis, Andrea Hodgkinson, Carmela De Santo, Shamyla Siddique, Ram Malladi, Kristian Brock, Jamie Cavenagh, Christina Yap, Charles Craddock, Paul Ferguson, Francis Mussai
Publikováno v:
Journal of Clinical Oncology
PURPOSE Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. Both lenalidomide (LEN) and